In this secondary analysis, we sought to determine whether baseline PSA levels in younger men enrolled in the PLCO Cancer Screening Trial were associated with the long-term risk of any PCa diagnosis and clinically significant PCa diagnosis. This evidence concerns the gene KLK3 and posterior cortical atrophy.